Week in Review: Fosun's Gland Pharma Approved for $814 Million IPO in India

Deals and Financings   India 's Gland Pharma, a Shanghai Fosun subsidiary that specializes in generic injected drugs, was approved to conduct an $814 million IPO in India ; Huadong Medicine in-licensed China rights to an antibody-drug conjugate targeting ovarian cancer from ImmunoGen in a $305 million agreement; 3D Medicines, a Beijing clinical-stage biopharma, completed a $225 million funding to develop immunotherapy drugs; Sirnaomics, a US-China company developing RNAi therapeutics, closed a $105 million Series D round from China investors; Zhaoke (Hong Kong) Ophthalmology Pharma acquired China rights to a myopia treatment from Nevakar in a $102 million deal; Beijing Immunochina Pharma raised $15 million in a C+ round of financing to support its portfolio of 12 CAR-T candidates; COVID-19 Pandemic Four China biopharmas have dosed a total of 60,000 people in Phase III trials of their COVID-19 vaccines without encountering any serious adverse events; Carelink of Shanghai acquired China rights from Japan 's FujiFilm for Avigan Tablets (favipiravir), a flu drug, to treat COVID-19; Trials and Approvals Suzhou Ascentage was granted China Priority Review for its NDA of a BCR-ABL inhibitor designed to overcome resistance in leukemia patients. Stock Symbols: (SHA: 600196; HK: 2196) (SHZ: 000963) (NSDQ: IMGN) (HK: 6855) Share this with colleagues: // //